Pagaya Technologies Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Pagaya Technologies Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.03B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $812.05M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $748.93M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $474.59M | Apr 25, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.00B | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $772.81M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $685.41M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $445.87M | Apr 25, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.39M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($401.41M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($128.44M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($302.32M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($91.15M) | Apr 25, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.83M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $66.84M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($24.40M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($251.51M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($5.81M) | Apr 25, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.21M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $76.57M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $74.38M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $150.93M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $66.21M | Apr 25, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.62M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $47.75M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | ($21.66M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($40.00M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $49.81M | Apr 25, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $17.74M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $20.19M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $22.41M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $6.62M | Apr 25, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.55B | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $1.21B | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.05B | Apr 25, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $960.46M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $775.28M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $468.38M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $279.66M | Apr 25, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.02M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $326.49M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $559.72M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $553.52M | Apr 25, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.90M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $23.06M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $10.95M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 25, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($862.65M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($944.04M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($542.64M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($414.20M) | Apr 25, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.33M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $187.92M | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $186.48M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | $309.79M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $190.78M | Apr 25, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $321.32M | Mar 12, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | (8) | Apr 25, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | (8) | Apr 25, 2024 |